Phase I/II Clinical Trial Combining FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 20 Mar 2017
At a glance
- Drugs CNVN 202 (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Genprex
- 07 Jun 2017 Biomarkers information updated
- 06 Jan 2017 Positive interim results published in the Genprex Media Release.
- 19 Feb 2014 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History